Trial Profile
Phase 2 Study to Evaluate Efficacy and Safety of CS-3150 in Patients with Essential Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Esaxerenone (Primary)
- Indications Essential hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 09 Jun 2016 New trial record